SCHEMBL21262609

SCHEMBL21262609

Oc1c(C(O)O)ccc(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.41
▸ CES1 P23141 3/20 0.41
▸ ADRA2A P08913 3/20 0.39
▸ ADRA2B P18089 3/20 0.39
▸ ADRA2C P18825 3/20 0.39
▸ ADRA1A P35348 2/20 0.39
▸ ADRB2 P07550 2/20 0.39
▸ ADRA1B P35368 1/20 0.39
▸ ADRB1 P08588 1/20 0.33
▸ ADRB3 P13945 1/20 0.33
▸ F2RL1 P55085 3/20 0.31
▸ CA3 P07451 1/20 0.31
▸ CA6 P23280 1/20 0.31
▸ CA5A P35218 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ CA5B Q9Y2D0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2737293 0.79 GABRA1 (0.50) CES2CES1ADRA2AADRA2BADRA2C
SCHEMBL30368289 0.73 ERN1 (0.42) CES2CES1CA3CA6CA5A
SCHEMBL78147 0.73 ERN1 (0.42) CES2CES1CA3CA6CA5A
SCHEMBL24724632 0.73 TSHR (0.47) CES2CES1ADRA2AADRA2BADRA2C
SCHEMBL7627962 0.70 CES2 (0.53) CES2CES1ADRA2AADRA2BADRA2C
SCHEMBL6222478 0.70 CES2 (0.36) CES2CES1ADRA2AADRA2BADRA2C
SCHEMBL5506954 0.69 ADRA2A (0.45) CES2CES1ADRA2AADRA2BADRA2C
SCHEMBL29597482 0.69 ADRA2A (0.45) CES2CES1ADRA2AADRA2BADRA2C
SCHEMBL1201506 0.68 CES2 (0.52) CES2CES1ADRA2AADRA2BADRA2C
SCHEMBL27588800 0.67 CES2 (0.45) CES2CES1ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019153080-A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2019-08-15 — — WO disclosed
Send feedback